Skip to content
Screener
Q3 '26Q2 '26Q1 '26Q4 '25Q3 '25
$53.23M+1.8%$48.14M+5.6%$44.14M+6.5%$62.14M+8.1%$52.29M+1.5%
$22.02M-11.0%$19.8M-8.9%$22.88M+7.4%$29.26M+22.8%$24.74M+10.0%
$31.21M+13.3%$28.34M+18.7%$21.25M+5.4%$32.89M-2.3%$27.55M-5.0%
58.6%+5.9pp58.9%+6.5pp48.2%-0.5pp52.9%-5.6pp52.7%-3.6pp
$9.36M+4.5%$9.74M+10.4%$9.6M-1.2%$8.96M-7.8%$8.96M-9.4%
$11.91M+2.1%$13.17M+8.6%$11.65M-6.9%$13.13M+10.6%$11.67M-6.1%
$18.36M+13.9%$16.83M+24.3%$18.47M+43.2%$16.39M+80.7%$16.12M+47.3%
$39.63M+7.9%$39.74M+15.2%$39.72M+13.1%$38.48M+25.5%$36.74M+10.5%
-$8.42M+8.4%-$11.4M-7.3%-$18.46M-23.3%-$5.59M—-$9.19M-116%
-15.8%+1.8pp-23.7%-0.4pp-41.8%-5.7pp-9%—-17.6%-9.3pp
$260K-47.4%$281K-32.1%$262K-10.0%——$494K+315%
$1.52M+6.5%-$243K-106%$1.09M-70.6%$1.56M-78.7%$1.42M-67.7%
-$811K+64.6%$515K+143%$1.49M+998%$40.05M+5,789%-$2.29M-192%
-$6.1M-11.3%-$12.16M-118%-$18.87M-65.5%-$44.08M—-$5.48M-682%
-11.5%-1.0pp-25.3%-13.0pp-42.7%-15.2pp-70.9%—-10.5%-12.3pp
-$6.31M+13.3%-$9.39M-7.5%-$16.6M-26.7%-$3.7M—-$7.27M-203%
-11.9%+2.1pp-19.5%-0.4pp-37.6%-6.0pp-6%—-13.9%-9.3pp
-$8.42M+8.4%-$11.4M-7.3%-$18.46M-23.3%-$5.59M—-$9.19M-116%

FAQ

What is Cytek Biosciences, Inc.'s revenue?
Cytek Biosciences, Inc. (CTKB) generated $207.6M in revenue over the trailing twelve months, up 5.5% year over year.
Is Cytek Biosciences, Inc. profitable?
Cytek Biosciences, Inc. is not currently profitable: it reported a net loss of $81.2M over the trailing twelve months, a -39.1% net margin.
What are Cytek Biosciences, Inc.'s profit margins?
Gross margin is 54.7% and operating margin is -21.1%, with a -39.1% net margin.
What is Cytek Biosciences, Inc.'s earnings per share?
Cytek Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-0.63.
Where does Cytek Biosciences, Inc.'s income statement data come from?
Every line is extracted from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.